首页> 美国卫生研究院文献>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research >A 10-Long Non-Coding RNA-Based Expression Signature as a Potential Biomarker for Prognosis of Acute Myeloid Leukemia
【2h】

A 10-Long Non-Coding RNA-Based Expression Signature as a Potential Biomarker for Prognosis of Acute Myeloid Leukemia

机译:10长非编码基于RNA的表达签名作为急性髓性白血病预后的潜在生物标志物。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAcute myeloid leukemia (AML) is a heterogeneous form of cancer, and it is one of the dominant causes of malignancy-related mortality in patients younger than 35 years old. Therefore, the treatment must be selected based on risk stratification. However, the methods to predict the clinical outcomes of AML are insufficient. Long non-coding RNAs (lncRNAs) are unable or barely able to code for proteins and have attracted remarkable interest because of their involvement in malignancies. Previous studies have proven that some lncRNAs contribute to the development and clinical outcome of AML. Our study constructed a risk stratification system for AML that will facilitate the prediction of clinical outcomes.
机译:背景急性髓细胞性白血病(AML)是一种异质性癌症,是35岁以下患者恶性肿瘤相关死亡率的主要原因之一。因此,必须根据风险分层选择治疗方法。但是,预测AML临床结果的方法不足。长的非编码RNA(lncRNA)无法或几乎不能编码蛋白质,并且由于它们参与了恶性肿瘤而引起了人们的极大兴趣。先前的研究证明,某些lncRNA有助于AML的发展和临床结果。我们的研究为AML建立了风险分层系统,这将有助于预测临床结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号